CABAZITAXEL ACCORD, CABAZITAXEL INTAS (Accord Healthcare Pty Ltd)
Product name
CABAZITAXEL ACCORD, CABAZITAXEL INTAS
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
138 (255 working days)
Active ingredients
cabazitaxel
Registration type
New generic medicine
Indication
CABAZITAXEL ACCORD, CABAZITAXEL INTAS (injection, concentrated) in combination with prednisone or prednisolone is indicated for the treatment of patients with metastatic castration resistant prostate cancer previously treated with a docetaxel containing regimen.